Kiora Pharmaceuticals (KPRX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, with voting on key proposals including director elections, executive compensation, auditor ratification, and an equity plan amendment.

• Shareholders of record as of April 16, 2026, are eligible to vote, with multiple voting methods available.

• The board recommends voting in favor of all proposals.

Voting matters and shareholder proposals

• Election of three Class II directors for a three-year term: Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D.

• Advisory vote on executive compensation (say-on-pay).

• Ratification of Haskell & White LLP as independent auditor for fiscal 2026.

• Approval of an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 1,500,000.

• Procedures for shareholder proposals and director nominations for the 2027 meeting are outlined.

Board of directors and corporate governance

• The board consists of seven members divided into three staggered classes.

• Most directors are independent per Nasdaq rules; the roles of CEO and chairman are separated.

• Committees include audit, compensation, and nominating/governance, each with defined charters and independent members.

• Directors are subject to a code of conduct, insider trading, and anti-hedging policies.